Flow cytometry (FCM) results illustrated that the frequency of tumor-infiltrating CD8+ T cells was 32.4% for the mice administrated with ULNPs-cRNAIL-2F@G, which was higher than that of ULNPs-cRNAIL-2F (23.9%), CLNPs-cRNAIL-2F (21.7%), and IL-2F (18.5%), indicating an enhanced antitumor immunity (Fig. 5G). The gene discussed is CD8A; the disease is neoplasm.